肝癌患者经导管肝动脉化学栓塞术后的睡眠障碍及其相关因素分析  

Sleep disorder and its associated factors of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization

作　　者：胥常琴[1] 刘艺薇[1] 

机构地区：[1]莱芜市人民医院肿瘤内科,山东莱芜271100

出　　处：《海南医学》2013年第14期2052-2055,共4页Hainan Medical Journal

摘　　要：目的初步探索肝癌患者经导管肝动脉化学栓塞术后的睡眠障碍发生情况及其相关因素。方法随机选取2010年1月至2012年6月在我院接受治疗、择期行经导管肝动脉化疗栓塞(TACE)术治疗的120癌患者为研究对象,采用自制《患者一般情况调查表》、匹兹堡睡眠质量指数量表、困扰症状量表、医院焦虑抑郁量表、功能状态评估量表收集有关信息,分析研究对象的睡眠障碍发生情况并采用Logistic回归分析其影响因素。结果共发放120套调查问卷,回收有效问卷116份,有效回收率为96.67%。本组病例睡眠障碍发生率为48.28%(56/116);睡眠障碍组患者身体功能状态、抑郁、困扰症状等均差于无睡眠障碍组;肝癌患者TACE术后睡眠障碍与年龄、困扰症状、抑郁有关(P<0.05)。结论年龄、困扰症状、抑郁等因素与肝癌TACE术后睡眠障碍的发生可能存在因果关系。Objective To explore the occurrence of sleep disorders and its related factors in patients with hepa- tocellular carcinoma after transcatheter arterial chemoembolization. Methods One hundred and twenty patients with hepatocellular carcinoma received catheter hepatic arterial chemotherapy embolization （TACE） were randomly selected in our hospital from January 2010 to June 2012. Pittsburgh sleep Quality Index scale, plagued symptom Scale, the Hospital Anxiety and Depression Scale, The Eastern Cooperative （3neology Group Scale were used to collect the relevant informa- tion. Logistic regression analysis was employed to analyze the influencing factors. Results A total of 120 question- naires were issued, and 116 valid questionnaires were retrieved, with the effective rate of 96.67%. The incidence of sleep disorders was 48.28% （56/116）. In the patients with sleep disorders, physical functional status, depression, and symptoms distress were worse than those without sleep disorders （P〈0.05）. Sleep disorders of patients with hepatocel- lular carcinoma after TACE were associated with age, distress, and depression. Condusion Age, distress, depression may have a causal association with the occurrence of sleep disorders in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization, but further research is still needed.

关 键 词：肝癌 经导管动脉化学栓塞术 睡眠障碍 相关因素 

分 类 号：R735.77[医药卫生—肿瘤]